PhenoScore: AI-based phenomics to quantify rare disease and genetic variation

Alexander J M Dingemans^{1,2}, Max Hinne², Kim M G Truijen¹, Lia Goltstein¹, Jeroen van Reeuwijk¹, Nicole de Leeuw¹, Janneke Schuurs-Hoeijmakers¹, Rolph Pfundt¹, Illja J Diets¹, Joery den Hoed³, Elke de Boer¹, Jet Coenen-van der Spek¹, Sandra Jansen⁴, Bregje W van Bon¹, Noraly Jonis¹, Charlotte Ockeloen¹, Anneke T Vulto-van Silfhout¹, Tjitske Kleefstra¹, David A Koolen¹, Hilde Van Esch⁵, Gholson J Lyon^{6,7}, Fowzan S Alkuraya⁸, Anita Rauch⁹, Ronit Marom¹⁰, Diana Baralle¹¹, Pleuntje J van der Sluijs¹², Gijs W E Santen¹², R Frank Kooy¹³, Marcel A J van Gerven², Lisenka E L M Vissers^{1*}, and Bert B A de Vries^{1*} ¹Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB, P.O. Box 9101, Nijmegen, the Netherlands. ²Department of Artificial Intelligence, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Thomas van Aquinostraat 4, 6525 GD Nijmegen, the Netherlands ³Language and Genetics Department, Max Planck Institute for Psycholinguistics, 6500 AH Nijmegen, the Netherlands ⁴Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands ⁵Center for Human Genetics, University Hospitals Leuven, University of Leuven, Leuven, Belgium. ⁶Department of Human Genetics and George A. Jervis Clinic, Institute for Basic Research in Developmental Disabilities (IBR), Staten Island, New York, USA ⁷Biology PhD Program, The Graduate Center, The City University of New York, New York, United States of America ⁸Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Rivadh, Saudi Arabia ⁹Institute of Medical Genetics, University of Zurich, Schlieren, 8952, Zurich, Switzerland. ¹⁰Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA. ¹¹Faculty of Medicine, University of Southampton, University Rd, Southampton, SO17 1BJ, UK ¹²Department of Clinical Genetics, Leiden University Medical Center, Leiden, the

Netherlands

¹³Department of Medical Genetics, University of Antwerp, Antwerp, Belgium. ^{*} corresponding authors (both authors contributed equally):

Lisenka.Vissers@radboudumc.nl, Bert.deVries@radboudumc.nl

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

While both molecular and phenotypic data are essential when interpreting genetic variants, prediction scores (CADD, PolyPhen, and SIFT) have focused on molecular details to evaluate pathogenicity — omitting phenotypic features. To unlock the full potential of phenotypic data, we developed PhenoScore: an open source, artificial intelligence-based phenomics framework. PhenoScore combines facial recognition technology with Human Phenotype Ontology (HPO) data analysis to quantify phenotypic similarity at both the level of individual patients as well as of cohorts. We prove PhenoScore's ability to recognize distinct phenotypic entities by establishing recognizable phenotypes for 25 out of 26 investigated genetic syndromes against clinical features observed in individuals with other neurodevelopmental disorders. Moreover, PhenoScore was able to provide objective clinical evidence for two distinct ADNP-related phenotypes, that had already been established functionally, but not yet phenotypically. Hence, PhenoScore will not only be of use to unbiasedly quantify phenotypes to assist genomic variant interpretation at the individual level, such as for reclassifying variants of unknown clinical significance, but is also of importance for detailed genotype-phenotype studies.

Keywords: artificial intelligence, VUS, machine learning, personalized medicine, facial recognition, deep phenotyping

Statement of conflict of interest: there is no conflict of interest.

1 Introduction

A significant portion of individuals with clinically and genetically heterogeneous rare diseases, such as neurodevelopmental disorders (NDD), has been molecularly diagnosed in the last decade using whole-exome sequencing (WES) [1–4]. Clinical WES data interpretation relies on filtering and prioritization for rare genetic variants in disease-gene panels, which are subsequently interpreted in the context of the patient's clinical presentation [5]. Whereas this strategy is essential to identify the disease-causing variant(s), it is estimated that, depending on the number of genes included in the panel, dozens of variants are prioritized as diagnostic noise [6] — and this number is expected to rise even more in the coming years with technological innovations such as genome sequencing finding their way into the diagnostic arena [7–9].

At the molecular level, several computational methods, such as MutationTaster [10], PolyPhen 11 [11], SIFT [12], CADD score [13], have been designed to predict variant pathogenicity. These tools 12 use diverse approaches, such as looking at the impact of the variant on protein structure (Muta-13 tionTaster, PolyPhen), taking conservation into account (MutationTaster, PolyPhen, SIFT) — or 14 trying to incorporate multiple sources of genomic information (CADD score). At the phenotypic 15 level, headway has been made by introducing Human Phenotype Ontology (HPO), systematically 16 capturing the presence of features observed in individuals with rare diseases [14]. However, equiv-17 alent to molecular tools, algorithms using these HPO data to quantify phenotypic HPO similarity 18 between individuals with genetic disorders would provide significant benefits to diagnose rare dis-19 ease. Such a quantitative phenotypic score could for instance assist with the interpretation of 20 genetic variants of unknown clinical significance (VUS), which constitute 10-30% of all variants 21 clinically assessed [4, 15]. Reducing the number of VUSs is of essence since studies have shown that 22 not all individuals and families respond similarly to the result of a VUS test-result, and usually do 23 not fully comprehend its meaning [16, 17], potentially leading to frustration, and/or distress due 24 to the uncertainty involving a possible diagnosis and course of disease. Importantly, VUSs have 25 also been shown to inflict inappropriate medical decisions [18, 19]. 26

Next to reclassifying VUSs, quantifying phenotypic HPO similarity at the cohort level could also
help to provide further steps towards personalized medicine by automatically recognizing distinct
phenotypic subtypes leading to more tailored clinical prognosis [20–22].

A branch of science that could assist in objectively quantifying phenotypic data is artificial intelligence (AI). AI has dramatically reformed the manner clinical data are processed and analyzed in recent years, with the AI revolution in medicine starting in pathology and radiology [23–26]. In genetics, these new techniques have been employed in assisted interpretation of genomic variants [27–29] and combining molecular and phenotypic evaluations, mainly looking at methods to use phenotypic data in HPO to automatically prioritize genetic variants [30–36]. Furthermore, ad-

vances in computer vision have led to the application of facial recognition technology in clinical 36 genetics [37–42]. Facial recognition is able to assist in the recognition of (neuro)developmental 37 syndromes, since the development of the brain and facial shape are closely linked [43-46] — and 38 therefore, it comes as no surprise that a significant part of genetic disorders have distinct facial 39 features [47]. However, not all genetic syndromes have a clear, recognizable facial gestalt, which 40 hinders methods solely looking at facial features. Moreover, a syndromic phenotype often includes 41 more than 'just the face'. Whereas tools have previously looked at either combining molecular 42 data with either HPO, or alternatively, with facial features [1, 39], an important area has been left unexplored, which combines the facial- and HPO data into an AI-framework to predict phenotypic 44 similarities without the need for genomic data input. Therefore, we developed PhenoScore: a next-45 generation open-source phenomics framework combining facial recognition technology with clinical 46 features, quantitatively collected in Human Phenotype Ontology (HPO) from deep phenotyping. 47

$_{48}$ 2 Results

49 2.1 The PhenoScore framework

PhenoScore is a framework that currently consists of two modules: a component that extracts 50 the facial features from a 2D facial photograph and a second module that takes HPO-based phe-51 notypic similarity into account (Figure 1). The AI-based framework joins these results in three 52 outputs: a Brier score and corresponding p-value, defining the individual's clinical similarity to 53 the syndrome assessed; a facial heatmap, highlighting important facial features for the syndrome; and, a visualization of the most important other (non-facial) clinical features. In the training 55 phase of PhenoScore, at first an age-, sex-, ethnicity- matched dysmorphic control is sampled from 56 our in-house database for every individual with the genetic syndrome of interest. Next, the facial 57 features are automatically extracted from the facial photographs for both affected individuals and 58 controls and the phenotypic HPO similarity is calculated (with several HPO terms and their child 59 terms first removed from the dataset, as these are either facial HPO terms to be processed by 60 the facial recognition module, or HPO terms that are deemed subjective and therefore at risk for 61 interobserver variability). A support vector machine (SVM), a widely used classification algorithm 62 in machine learning, is trained on these features, resulting in a trained classifier that can be used to 63 generate a score for individuals, suspected to have the syndrome of interest. If we are interested in quantifying phenotypic (sub)groups, a permutation test is added during the training phase, deter-65 mining whether the trained classifier performs better than random chance — providing evidence 66 whether the two groups are distinguishable by PhenoScore. Finally, to provide insight into what 67 PhenoScore is doing and to learn more about the investigated syndromes, explainable AI is incor-68

⁶⁹ porated into PhenoScore as well, using Local Interpretable Model-agnostic Explanations (LIME)
⁷⁰ [48, 49]. LIME works by generating random perturbed input data and inspecting the change in
⁷¹ predictions, thereby obtaining data on the relative importance of each feature. By using LIME for
⁷² both the facial- and HPO data, PhenoScore can generate facial heatmaps and visualizations on
⁷³ the most important clinical features.

⁷⁴ 2.2 Proof-of-Concept using PhenoScore for Koolen-de Vries syndrome

First, we investigated whether using our combined PhenoScore was actually an improvement on solely using either facial- or phenotypic data. The SVM was trained on both separate feature sets alone (e.g. HPO and facial features) and subsequently compared with the classification performance of PhenoScore. To measure classification performance, the Brier score [50] was chosen as the performance measure to focus on: it is defined as the mean squared difference between predicted outcome and observed actual outcome (lower is better). Next to that, we also report the area under the receiving operator curve (AUC; higher is better).

To demonstrate the power of the PhenoScore framework, we first performed a proof-of-concept 82 study using 63 individuals with Koolen-de Vries syndrome (KdVS, OMIM #610443, Figure 2), 83 caused by either proven pathogenic loss-of-function variants in KANSL1 (n=11) or the 17q21.31 84 microdeletion (n=52). KdVS most prominent features reported in literature include hypotonia, 85 intellectual disability, and joint laxity [51-53], for which the interdependence in our modelling is 86 preserved using the graph structure of the HPO terms (Figure 2). Running Phenoscore on the 63 87 individuals with KdVS, we confirm the improvement on overall predictive performance when using 88 both facial and clinical features compared to using either one alone (Brier score 0.106 or AUC 0.9289 for PhenoScore, in contrast to 0.130/0.90 when using only facial data and 0.121/0.90 when using 90 only phenotypic data, Table 1). 91

We next randomly excluded four individuals (facial images shown in Figure 2) from the train-92 ing dataset and retrained PhenoSscore, allowing us to test the performance of PhenoScore when 93 treating them as if diagnoses of KdVS were unknown. We then used PhenoScore to predict the sim-94 ilarity of these four individuals when comparing them with 59 remaining individuals with KdVS in 95 the training set. PhenoScore output was displayed using LIME, providing heatmaps of prioritized 96 facial information according to PhenoScore (Figure 2). In addition, the most important clinical 97 features according to PhenoScore to be predictive for KdVS were summarized by numerically scor-98 ing and ranking them. According to PhenoScore, the nose and eyes are the most important facial qq parts when recognizing KdVS — while the presence of nevi, joint laxity, hypotonia, hypermetropia, 100 and EEG abnormalities are the clinical features of interest. This is completely consistent with ex-101 pert opinion and the literature [51-53] and shows that the prediction is based on the extracted 102

facial features from 2D photos and phenotypic data in HPO — harnessing the power of both and
 outperforms the separate predictions.

¹⁰⁵ 2.3 Expanding PhenoScore to 26 syndromes

After our proof-of-concept using KdVS, we next assessed the performance of PhenoScore for the classification of other genetic syndromes too. Hereto, we selected 25 syndromes (Table 1 and Supplemental Table 1) including both clinically well-recognizable syndromes based on facial gestalt, such as Kleefstra syndrome (OMIM #610253, caused by pathogenic variants in *EHMT1*), Helsmoortel-van der Aa syndrome (OMIM #615873, caused by pathogenic variants in *ADNP*) and Coffin-Siris syndrome (OMIM #135900, *ARID1B*), but also more recently identified syndromes for which facial gestalt is less prominent, including IDDAM (OMIM #615032, *CHD8*) and IDDFBA (OMIM #618089, *FBXO11*).

Analyzing all these syndromes, we demonstrate that PhenoScore is a statistically significant improvement on using either feature set alone, and therefore, the whole is more than the sum of its parts in this case (median Brier score 0.22 for facial features on the whole dataset, 0.16 for HPO data and 0.15 for PhenoScore, p < 0.001; median AUC 0.71 for facial features, 0.85 for HPO data and 0.87 for PhenoScore, p < 0.001, Table 1). Furthermore, our post hoc checks show that there was no overfitting using the internal control dataset (see Supplemental Table 2).

For 25 of 26 syndromes (96%), PhenoScore was able to identify predictive features that characterized these syndromes and recognized a distinct phenotypic entity (Table 1). As expected, and visualized in the LIME heatmaps (Figure 3), these features corresponded remarkably well with those described in the literature. For instance, for Helsmoortel-van der Aa syndrome (OMIM #615873), the facial- and forehead regions are prioritized in the predictions, as seen in the generated heatmap (Figure 3d) — corresponding with the known dysmorphic characteristics for this syndrome.

Moreover, for a genetic syndrome which lacks explicit facial features, like IDDAM, apparent 127 overgrowth symptoms, such as macrocephaly and tall stature, were identified as significant predic-128 tors, while no relevant facial features were extracted, as displayed in the heatmap and summarized 129 ranking scores. A similar case is made for the genetic disorder associated with pathogenic variants 130 in DYRK1A: while the classifier based only on the facial features does not provide any meaningful 131 predictions, the addition of other phenotypic data in HPO did allow PhenoScore to distinguish 132 this syndrome as a phenotypic entity. These data suggest that PhenoScore objectively extracts, 133 distinguishes, and visualizes the specific clinical features for genetic syndromes and highlights that 134 the addition of non-facial phenotypic data in HPO is essential. 135

¹³⁶ 2.4 PhenoScore is scalable as it requires only a low number of individ ¹³⁷ uals for training

Most genetic disorders are individually rare, with sometimes only 3-5 individuals reported world-138 wide. We therefore next investigated how many data sets PhenoScore requires for accurate clas-139 sification of a specific syndrome. We checked the performance of PhenoScore while increasing the 140 number of individuals in the complete dataset of 26 genetic syndromes with the combination of 141 facial- and HPO features, starting with only 2 individuals. This analysis revealed that, with three 142 individuals to train on, the median classification performance for the investigated syndromes is 143 already clinically acceptable (AUC 0.85; Figure 4). The classification performance can be further 144 improved when the training sets increase in size (median AUC 0.90 with seven individuals, 0.95 145 for 17 individuals). 146

¹⁴⁷ 2.5 Use case 1: Objective clinical quantification for the interpretation ¹⁴⁸ of molecular VUS

To display the power of PhenoScore in the clinical interpretation of variants at an individual 149 level, we reassessed reported VUSs (ACMG class 3) in the Radboudumc department of Human 150 Genetics. These individuals were not included in the training of PhenoScore and can therefore 151 be considers real out-of-sample cases. In total, we identified 15 individuals in whom a class 3 152 variant was reported in either of 11 of the 26 syndromes (Supplemental Table 3). PhenoScores 153 were calculated, and when using thresholds of ≤ 0.30 (for 'no phenotypic match') and ≥ 0.70 (for 154 'phenotypic match'), PhenoScore was able to classify 9/15 (60%) of the cases as either match (n=2) 155 or no match (n=7). The other 6 cases had an inconclusive PhenoScore result (scores >0.30 but 156 <0.70). Interestingly, for only 1/9 cases for which PhenoScore was conclusive, the clinician made 157 a decision for the VUS based on the phenotype — PhenoScore was essential for the other eight 158 cases. Importantly, parallel functional follow-up for 4 variants confirmed the PhenoScore outcome, 159 whereas for the remaining cases, functional follow-up was inconclusive. 160

¹⁶¹ 2.6 Use case 2: Next-generation phenomics for the generation of sophis-¹⁶² ticated genotype-phenotype correlations

Genotype-phenotype studies for rare diseases are often performed to gain insight into the clinical spectrum, which allows clinicians to provide a more accurate counseling of individuals with rare diseases. Molecularly, the toolkit to gain in-depth insight into aspects of pathogenicity is generally applied in a research setting, and thus often not readily available for diagnostic follow-up. From a clinical perspective, analyses are often limited to cluster analysis and/or principle component anal-

¹⁶⁸ ysis, but without being able to determine what aspects clinically distinguish subtypes, if identified.

¹⁶⁹ We tested whether PhenoScore can improve these hypothesis-driven approaches to distinguish, or ¹⁷⁰ discover, clinical subtypes.

For two genetic syndromes in our dataset, i.e. SATB1-associated neurodevelopmental disorders 171 (OMIM #619228)[54], and Helsmoortel-Van Der Aa Syndrome (OMIM #615873, caused by dis-172 ruption of ADNP [55]), it has previously been determined that there are (at least) two molecular 173 subtypes. For SATB1, it has also been acknowledged that individuals with missense variants and 174 those with loss-of-function variants, are clinically different. As proof-of-concept, PhenoScore con-175 vincingly distinguished two groups for SATB1 (Brier score 0.18, AUC 0.81, p = 0.02), confirming 176 the original results [54]. For ADNP, it was recently shown that individuals with pathogenic variants 177 in ADNP show one of two distinct methylation signatures (type 2, when variant affects position 178 between c.2000 and c.2340; or type 1, when the variant occurs outside of this interval), suggesting 179 the possibility of two syndromes associated with this gene [56]. Clinically, however, these individu-180 als could not be conclusively distinguished [57]. Prior to determining PhenoScores, we categorized 181 the individuals as having either a type 1 or type 2 ADNP signature. Initially, we assessed the 182 performance of PhenoScore using only individuals (n=33) for whom both facial photographs and 183 clinical features were available, but failed to identify a statistically significant difference between 184 the groups (Brier 0.30, AUC 0.52, p = 0.35). However, using the ADNP Human Disease Gene 185 website, we could collect HPO-only data of more individuals. Using this dataset, we obtained clin-186 ical features in HPO of 58 individuals (29 in each group), and on these data PhenoScore did show 187 evidence for two phenotypically different entities (Brier 0.24, AUC of 0.71, p = 0.02). Inspecting 188 the generated PhenoScore explanations for clinically relevant differences (Figure 5), it seems that 189 recurrent infections and gastrointestinal problems (reflux, constipation, feeding difficulties) are 2-3 190 times more common in type 2 than in type 1. 191

$_{192}$ 3 Discussion

PhenoScore provides a significant step in the advancement of AI in clinical genetics: a novel machine learning phenomics framework unifying facial and phenotypic features using high-quality data directly from affected individuals instead of generic phenotypic descriptions of a syndrome. Others have introduced AI in this domain of healthcare, with for instance the application of using HPO terms to prioritize genetic variants while comparing individuals to the known phenotype of disorders in the literature [30, 31, 36, 58]. The utilization of facial recognition technology to assist clinicians in diagnosing individuals has been successful too, with most, unfortunately, relying on proprietary commercial algorithms [35, 37–42]. We now show a next step, with an open-source

framework that takes the complete phenotype into account, including both facial- and phenotypic features directly from affected individuals, and uses AI to provide a score on how well the patient's phenotype (as a whole) matches individuals with a known syndrome.

PhenoScore detected a recognizable phenotype in all but one investigated genetic syndrome 204 (25/26; 96%), and only needed as little as three individuals for classification performance. In this 205 manner, PhenoScore assists clinicians and molecular biologists in quantifying phenotypic similarity, 206 at both an individual- and group level for theoretically all OMIM-listed disorders. The sole disorder 207 for which PhenoScore failed to identify a phenotype was for variants in ACTL6A. Interestingly, this is the only of 26 syndromes that has not been recognized by OMIM as a genetic disorder, 209 due to lack of (phenotypic) evidence in combination with the fact that individuals in whom the 210 ACTL6A variants were uncovered, had not been tested by trio whole exome sequencing. OMIM 211 therefore concluded that it is uncertain that the variants in ACTL6A cause the phenotype of these 212 individuals. 213

Assisting variant classification of VUSs is an obvious use-case for PhenoScore. Of course, several 214 in vitro functional assays are available to assess variant pathogenicity, but so far these are mostly 215 used for genes involved in oncogenetic disorders [59, 60]. For neurodevelopmental disorders, these 216 assays are scarce since they need to be developed on a gene-per-gene basis, and for these rare 217 disorders, this is usually not cost-effective and solely done for research purposes. Other methods 218 to assess genetic variants include protein structural analysis [61], which however still relies on 219 the availability of relevant protein structures. Our approach theoretically works for any (genetic) condition with a recognizable phenotype, provided there are sufficient individuals for training the 221 algorithm, and that HPO data and 2D-facial photos are available. Indeed, PhenoScore is as good as 222 its input data. In the field of rare diseases, however, major efforts are put in obtaining these high-223 quality quantitative phenotypic data, as for instance shown by collections of datasets by the Human 224 Disease Gene website series [62], GeneReviews, DECIPHER and OMIM [63–65]. Here, the use of 225 HPO terms, in combination with the use of Resnik scores (ensuring that the use of similar HPO 226 terms leads to comparable results), minimizes the effect of variation in clinical terminology used 227 between clinicians, and thus deriving the most benefits from the AI-based quantitative phenotypic 228 framework. 229

PhenoScore also helped to objectively obtain genotype-phenotype correlations, by training on suspected phenotypic subgroups combined by permutation testing to quantify statistical significance. We replicated earlier findings in *SATB1*, quantitatively underscoring that truncating variants lead to a significantly different phenotype than missense variants [54].Whereas for SATB1 the different phenotypes were also subjectively identifiably from expert opinion, the power of PhenoScore was shown by demonstrating the existence of two distinct phenotypes associated with

Helsmoortel-van der Aa syndrome. Molecularly, two different methylation signatures have been 236 published, which were discriminated by the mutation location in ADNP [55–57], but for which 237 clinically, no differences were observed. PhenoScore was not only able to prove the existence of 238 clinically distinctive groups, but also provided insight into which clinical features separates the two 239 clinical entities. For instance, neurodevelopmental problems are more common in the ADNP-type 240 1, while gastrointestinal symptoms, recurrent infections and short stature are 2-3 times more com-241 mon in ADNP-type 2. These clinical features have a significant impact on an individual's quality of 242 life, hence, by identifying these subgroups, PhenoScore directly impacted clinical recommendations 243 for these individuals and families. 244

These subgroup analyses could in theory be performed for every (genetic) syndrome caused 245 by different types of SNVs or CNVs — which is the case in a significant portion of the currently 246 ~ 1600 known NDD genes. While recognizing specific novel subgroups is a first step towards 247 personalized medicine and provides improved clinical prognosis and recommendations (as shown 248 for the subgroups in ADNP and SATB1, not finding a distinct difference is useful too: it helps to 249 assess whether two types of genetic variation have the same effect (i.e. whether missense variants 250 actually cause haploinsufficiency). Furthermore, PhenoScore could be utilized to find phenotypic 251 outliers, of whom the molecular mechanism leading to disease might be novel. By quantifying 252 the complete phenotypic similarity and visualizing differences between (sub)groups, PhenoScore 253 empowers detailed genotype-phenotype studies, leading to new insights on both the genetic- and phenotypic level.

The discriminating clinical features for the two *ADNP*-related disorders were not represented in a different facial gestalt, emphasizing the importance of adding HPO data across all organ systems. In addition, given that these two phenotypic subgroups were not identified from more subjective clinical analysis, using a predefined structured AI method of phenotypic data analysis provides novel insights. To facilitate easy use in routine clinical care, it is, however, also of paramount importance to be able to intuitively understand the AI output. We therefore also provided graphical output such as facial heatmaps to visualize which (facial) features specified PhenoScore output.

Detailed genotype-phenotype analysis could in theory be performed for every (genetic) syn-263 drome, suggesting that PhenoScore may be a valueable tool to also foster novel molecular insights. 264 That is, for many of the 1,600 known genes associated to an NDD phenotype, multiple types of 265 genetic variants (e.g. SNVs and CNVs) may cause the disorder. Whereas the molecular mecha-266 nism for CNVs often relate to dosage-sensitivity, such as haploinsufficiency, the mechanisms for 267 SNVs leading to missense variants in those genes, are often less pertinent. PhenoScore may assess 268 phenotypic differences between individuals with the same syndrome, but caused by either CNVs 269 ('group 1') or missense variants ('group 2') and help to establish whether those missense variants 270

²⁷¹ are also haploinsufficient. Similarly, PhenoScore could be utilized to find phenotypic outliers, of ²⁷² which the molecular mechanism leading to disease might be novel.

In conclusion, PhenoScore bridges a gap between the fields of AI and Clinical Genetics by 273 quantifying phenotypic similarity, assisting not only in genetic variant interpretation, but also fa-274 cilitating objective genotype-phenotype studies. We showcased its use for individuals with NDD, 275 whose phenotypes were captured using HPO. PhenoScore can, however, also easily be used be-276 yond the field of rare disease, as adjustments to use other (graph-based) ontologies, such as for 277 instance SNOMED [66], can readily be integrated. The PhenoScore AI-based framework is thus 278 easily extended to other domains of (clinical) genetics, or even to completely different branches of 279 medicine, due to its open-source modular design. 280

²⁸¹ 4 Materials and Methods

282 4.1 Inclusion of individuals

The literature was searched for clinical studies which included facial photographs for 26 randomly 283 selected genetic syndromes associated with NDD. The photographs were collected and clinical 284 features, if available, were converted to HPO terms. Currently, PhenoScore is trained using data 285 of 501 non-familial individuals diagnosed with one of the 26 different genetic syndromes, collected 206 from 81 different publications (see Table 1 for the complete overview of the demographics per 287 genetic syndrome and Supplemental Table 1 for all publications used as sources for the data used 288 in this study). The phenotypic data were uploaded to the specific gene website in the HDG website series [62] to ensure their public availability. The use of these data was approved by the ethical 290 committee of the Radboud university medical center (#2020-6151). 291

²⁹² 4.2 Data processing

To obtain a representative control group for our machine learning models, for each syndrome with n293 individuals, n age-, sex- and ethnicity matched controls with a neurodevelopmental disorder seen at our outpatient clinic at the Radboud university medical center were selected as described previously 295 [39] from our internal control database with over 1200 individuals with both facial image and 296 quantitative phenotypic data available (for a complete overview of the workflow of this study, please 297 see Figure 1). When no matched control was available, that particular individual was excluded from 298 our analysis. Next to that, when individuals were related to each other, one individual was chosen 299 (based on the quality of the picture) from that family. For each syndrome, cross-validation was 300 used to assess the performance of the classifiers. The number of folds during the cross-validation 301 procedure varied due to the considerable variation in dataset size: for every syndrome with at 302

least ten individuals, 5-fold cross-validation was used — otherwise, leave-one-out cross-validation was chosen. As the selection of the randomly selected controls might significantly influence the performance, for each genetic syndrome, different controls were sampled during ten random restarts and the mean AUC and Brier scores of these ten iterations were noted. Furthermore, to confirm the source of the data did not significantly influence our results, we did post hoc checks by using not only the individuals from our internal control dataset, but the other included syndromes as well as controls.

4.3 Extraction of facial features

The facial features were extracted using VGGFace2 [67, 68], a state-of-the-art facial recognition method that utilizes a deep neural network. To avoid overfitting, we did not retrain VGGFace2, but used its pretrained weights instead. The images were then processed by VGGFace2 and the representation in the penultimate layer of the network was obtained. This representation was then used as the facial feature vector. The process was performed as described previously: for the entire (technological) methodology, please see [69].

317 4.4 Phenotypic similarity

To create a homogeneous dataset, the phenotype of every individual in this study was manually 318 converted into HPO terms [14]. A selection of HPO terms and all their child nodes were re-319 moved to eliminate any subjectivity in assessing an individual. These were *Behavioral abnormality* 320 (HP:0000708), Abnormality of the face (HP:0000271), Abnormal digit morphology (HP:0011297), 321 Abnormal ear morphology (HP:0031703), Abnormal eye morphology (HP:0012372), and every node 322 which is a child node of either of these. We chose these terms as these are either facial features (to 323 be assessed by our facial recognition model) or are suspected to vary across clinicians doing the 324 assessment of an individual. In this manner, 3810 HPO terms were excluded with 12259 terms 325 remaining. To further reduce possible inter-observer variability, the phenotypic similarity between 326 individuals was calculated using the Resnik score [70], since it takes the semantic similarity between 327 symptoms into account. The Resnik score utilizes the information content (IC) of a symptom. In 328 an ontology akin to the HPO, the IC of a specific term can be seen as a measure of the rarity of a 329 term. Naturally, terms closer to the root of the HPO tree have a lower IC. For instance, Abnormal-330 ity of the nervous system (HP:0000707) has an IC of 0.60. In contrast, Focal impaired awareness 331 motor seizure with dystonia (HP:0032717), significantly further down the HPO tree, has an IC 332 of 8.97. This corresponds to our intuition: rare features provide more information than common 333 features — since the prior probability of an individual reporting a rare symptom is, by definition, 334 smaller. The Resnik score uses this property by defining the similarity between two HPO terms as 335

the IC of their most informative (that is, with the highest IC) common ancestor in the HPO tree. 336 Since terms lower in the tree have a higher IC, the most informative common ancestor corresponds 337 to the last HPO term, which has both compared HPO terms as child nodes when traversing the 338 tree downwards. As an example: for the HPO terms Reflex seizure (HP:0020207) and Focal motor 339 seizure (HP:0011153), the most informative common ancestor is Seizure (HP:0001250), which has 340 an IC of 1.70. The Resnik similarity score for Reflex seizure (HP:0020207) and Focal motor seizure 341 (HP:0011153) is therefore 1.70. Next, we used the best-match average (BMA) to calculate the 342 similarity between two individuals (who usually report multiple HPO terms), in which the average 343 is taken over all best-matched pairwise semantic similarities, as previous studies determined it to 344 be most effective [71]. The idea is similar to that discussed above: if two individuals share a rare 345 symptom (Focal impaired awareness motor seizure with dystonia (HP:0032717), for instance), they 346 are more similar than two individuals who only share a common symptom such as Abnormality of 347 the nervous system (HP:0000707). The Resnik similarity score was calculated for every individual 348 and control and then averaged for both groups. In the end, this led to a nx^2 matrix for the HPO 349 features: an average similarity score for each individual versus affected individuals and a score 350 for each individual versus the control group. We calculated the BMA Resnik score between the 351 individuals using the phenopy library in Python 3.8 [72]. 352

4.5 Construction of machine learning model

Finally, the data were used to train a binary classifier. We selected a support vector machine (SVM) as our classifier, known for its excellent overall performance in classification tasks. The SVM was trained using the standard radial basis function kernel and a hyperparameter grid search for C.

After determining the predictive performance of the model, we determined how many data the 358 classifier needed for an acceptable classification performance in clinical practice. Per syndrome, 359 we started with randomly selecting two individuals and two matched controls, training the model 360 on those, and using the rest of the individuals (n-2), as one individual is used as training data) 361 and matched controls as a test set (two individuals that were not used in the first iteration as 362 the grid search in the SVM classifier needs at least two training samples). We ran ten random 363 restarts, randomly selecting another individual and matched control in each iteration. In each 364 restart, leave-one-out cross-validation was employed. The Brier score and AUC were noted and 365 averaged over the ten restarts. Next, the size of the training set was increased by one patient, and 366 one matched control, still using the rest of the individuals (now n-3) and matched controls as the test set. By increasing the training set by one individual and matched control each time and recording the performance, the model's performance with an increasing number of individuals is 369

370 assessed.

The Wilcoxon signed-rank test was used to determine statistically significant differences in the performance of the classifiers since it is a non-parametric test and, therefore, suitable — as these data are not normally distributed.

³⁷⁴ 4.6 Explainability of predictions

To see which features contained important information for our model, we generated Local Interpretable Model-agnostic Explanations (LIME) [48, 49]. The main idea of this method is to train a relatively simple local surrogate model to approximate the predictions of the model of interest. Next, the original input data is perturbed, and the corresponding change in predictions is inspected to obtain the relative importance of individual features. A key advantage of LIME is that it is applicable to any model and can therefore be used directly on top of our pipeline.

When using LIME for image data, it is common practice to divide the image into several segments, called superpixels. Therefore, we generated a raster of 25×25 pixel squares for each facial image, randomly offset for each of 100 runs. Each pixel's relative importance was averaged over these runs to obtain a higher resolution visualization of their significance. For the clinical data, the original HPO features were perturbed to obtain the most significant ones in predictions. In this case, LIME uses input data in which some HPO features are added and some are removed from the input data, to see what the effect on the prediction is.

LIME explanations were generated for the individuals with the five highest predictions scores. These explanations were then averaged, to obtain an overall explanation representative for that specific genetic syndrome. To ensure only real important features were recovered, only HPO terms that were identified in at least three individuals were used in this analysis.

³⁹² 4.7 Hypothesis testing

To see whether we could extend the use of our classifier to other applications than the reclassifi-393 cation of VUSs, we designed a random permutation test for the performance of our model. This 394 enables the testing of a specific hypothesis for facial features, phenotypes, or both. An example 395 would be determining whether a newly discovered genetic syndrome consists of several (pheno-396 typic/facial) subtypes. Using our framework, we trained a classifier on the labels of the suspected 397 subgroups. By performing a random permutation test, a *p*-value is calculated, so that the appear-398 ance of the subgroups can be quantified. For a complete overview of the exact methodology of this 399 permutation test, please see the Supplemental Methods. 400

⁴⁰¹ Data and code availability

⁴⁰² The code of PhenoScore created during this study is freely available at

https://github.com/ldingemans/PhenoScore, to enable anyone to apply PhenoScore to their own dataset. Included in PhenoScore are two examples: the data for the *SATB1* subgroups (positive example) and random data (negative example). The used dataset in this study is not publicly available due to both IRB and General Data Protection Regulation (EU GDPR) restrictions since the data might be (partially) traceable. However, access to the data may be requested from the data availability committee by contacting the corresponding author.

$_{409}$ Acknowledgements

We are grateful to the Dutch Organisation for Health Research and Development: ZON-MW grants 410 912-12-109 (to B.B.A.d.V. and L.E.L.M.V.), Donders Junior researcher grant 2019 (B.B.A.d.V. and 411 L.E.L.M.V.) and Aspasia grant 015.014.066 (to L.E.L.M.V.). The aims of this study contribute 412 to the Solve-RD project (to L.E.L.M.V.), which has received funding from the European Union's 413 Horizon 2020 research and innovation program under grant agreement No 779257. R.F.K acknowl-414 edges financial support of the Research Fund of the University of Antwerp (Methusalem-OEC 415 grant – "GENOMED"). The work of G.J.L. is supported by New York State Office for People 416 with Developmental Disabilities (OPWDD) and NIH NIGMS R35-GM-133408. 417

Author information

419 Conceptualization: A.J.M.D, M.H, L.E.L.M.V, B.B.A.d.V, M.A.J.v.G; Data curation: A.J.M.D,

- 420 K.M.G.T, L.G, J.V.R, N.d.L, J.S.H, R.P, I.J.D, E.d.B, J.d.H, J.V.d.S, S.J, B.W.V.B, N.J, A.T.V.V.S,
- 421 T.K, D.A.K, F.K, H.V.E, G.J.L, F.S.A, A.R, R.M, D.B, P.J.v.d.S., G.S, L.E.L.M.V, B.B.A.d.V;
- 422 Formal Analysis: A.J.M.D, M.H; Funding acquisition: L.E.L.M.V, B.B.A.d.V; Investigation: A.J.M.D,
- ⁴²³ M.H; Modelling: A.J.M.D, M.H.; Software development: A.J.M.D; Writing original draft: A.J.M.D,
- 424 M.H, L.E.L.M.V, B.B.A.d.V, M.A.J.v.G; Writing review and editing: all authors.

425 Ethics declaration

In this study, data from the Biobank 'Intellectual Disability', which is part of the Radboud Biobank initiative (for more information, see [73] or https://www.radboudumc.nl/en/research/radboudtechnology-centers/radboud-biobank) were used. Within this biobank, phenotypic and molecular data have been systematically captured for individuals with (non-)syndromic ID referred to the

- 430 Radboud university medical center. The use of this dataset was approved by the ethical committee
- 431 of the Radboud university medical center (#2020-6151). Furthermore, the authors declare no
- 432 competing interests.



Figure 1: Here, the global workflow of this study is displayed, with the training and construction of PhenoScore on the left side. n individuals and n age-, sex- and ethnicity matched controls are selected for each syndrome. The facial features are extracted using a convolutional neural network, VGGFace2, and a support vector machine (SVM) is trained on these features. In parallel, the phenotypic similarity of individuals and controls is calculated, and a SVM is trained on those scores. Finally, a SVM is trained on both the facial features and the HPO similarity combined. On the right side of the figure, the trained classifier is used for a new individual with a VUS. Again, the phenotypic similarity and facial distances are calculated, and these are used as input for the trained SVM. The output is a score and assesses whether the individual of interest has that specific syndrome, thus the VUS being (likely) pathogenic.

Table 1: The number of individuals per gen and an age-, sex- and ethnicity control with distribution, the median age and the results syndrome is shown — with the numbers sho almost all syndromes, the combination of fa table displays the calculated p -values for the as expected when inspecting the classificatio	etic syndrome a neurodevela s of the suppc own correspon orial- and phe cial- and phe investigated n results.	e included in our an opmental disorder is art vector machine (ding to the mean of notypic data is an i syndromes using the	alysis are shown a available (other SVM) classifier the scores duri mprovement ove e random permu	. here. For every inc wise, the individual are displayed here. ag the ten iterations r using either datas tation test. All but	lividual, a faci was excluded The Brier scor in which mat et alone. Furt one are signifi	al photograph.). Per genetic for which lo ched controls v hermore, the l cant at the 0.0	, phenotypii syndrome, t wer is bett vere sample ast column 5 (and 0.01	c data, the sex er, per d. For of this) level,
Gene/genetic syndrome	OMIM number	Number of individuals	Male/female (%)	Age (median in years)	Facial data only	HPO data only	PhenoScore	<i>p</i> -value
22q11 deletion syndrome	611867	19	10/9~(53%/47%)	5.0	0.189	0.146	0.124	< 0.001
ACTL6A	NA	3	$2/1 \ (67\%/33\%)$	6.0	0.255	0.299	0.291	0.98
ADAT3 (NEDBGF)	615286	6	$3/3\ (50\%/50\%)$	7.5	0.180	0.075	0.059	< 0.001
ADNP (Helsmoortel-van der Aa syndrome)	615873	33	15/18~(45%/55%)	5.0	0.209	0.156	0.145	< 0.001
ANKRD11 (KBG syndrome)	148050	22	15/7~(68%/32%)	9.5	0.236	0.196	0.180	< 0.001
ARID1B (Coffin-Siris syndrome)	135900	34	16/18 (47%/53%)	6.0	0.155	0.087	0.070	< 0.001
CHD3 (Snijders Blok-Campeau syndrome)	618205	27	11/16~(41%/59%)	10.0	0.216	0.148	0.144	< 0.001
CHD8 (IDDAM)	615032	20	15/5 (75%/25%)	11.0	0.254	0.174	0.163	< 0.001
DDX3X (MRXSSB)	300958	29	0/29~(0%/100%)	8.0	0.171	0.030	0.025	< 0.001
DYRK1A (MRD7)	614104	13	7/6~(54%/46%)	12.0	0.258	0.192	0.174	< 0.001
EHMT1 (Kleefstra syndrome)	610253	29	12/17~(41%/59%)	6.0	0.220	0.107	0.090	< 0.001
FBX011 (IDDFBA)	618089	18	$14/4 \ (78\%/22\%)$	7.0	0.265	0.250	0.247	< 0.001
KANSL1 (Koolen-De Vries syndrome)	610443	63	28/35 $(44%/56%)$	6.0	0.130	0.121	0.106	< 0.001
KDM3B (Diets-Jongmans syndrome)	618846	13	7/6~(54%/46%)	7.0	0.262	0.185	0.194	< 0.001
MECP2 duplication (MRXSL)	300260	5	$5/0\ (100\%/0\%)$	8.0	0.169	0.214	0.173	< 0.001
MED13L (MRFACD)	616789	22	13/9~(59%/41%)	6.0	0.235	0.140	0.124	< 0.001
PACS1 (Schuurs-Hoeijmakers syndrome)	615009	15	$10/5 \ (67\%/33\%)$	4.0	0.240	0.146	0.140	< 0.001
PHIP (Chung-Jansen syndrome)	617991	16	9/7~(56%/44%)	12.0	0.236	0.274	0.242	< 0.001
PPM1D (Jansen-de Vries syndrome)	617450	11	5/6~(45%/55%)	7.0	0.269	0.189	0.163	< 0.001
PURA (NEDRIHF)	616158	33	$18/15\ (55\%/45\%)$	9.0	0.232	0.126	0.110	< 0.001
SATB1 (truncating, DEFDA)	619228	8	$3/5\;(38\%/62\%)$	6.5	0.260	0.170	0.164	< 0.001
SATB1 (missense, Kohlschutter-Tonz syndrome-like)	619229	11	5/6~(45%/55%)	11.0	0.123	0.231	0.229	< 0.001
SON (ZTTK syndrome)	617140	25	$13/12\ (52\%/48\%)$	6.0	0.234	0.133	0.123	< 0.001
TRIO (MRD63)	618825	×	3/5~(38%/62%)	10.5	0.161	0.157	0.159	< 0.001
WAC (DeSanto-Shinawi syndrome)	616708	6	$3/6\ (33\%/67\%)$	4.0	0.185	0.204	0.176	< 0.001
YY1 (Gabriele-de Vries syndrome)	617557	9	5/4~(56%/44%)	9.0	0.175	0.219	0.199	0.002



Figure 2: A) The HPO terms of all included individuals with Koolen-de Vries (KdVS) are shown here. HPO terms present in 20% or more of the individuals are annotated with text, and larger nodes correspond to a higher prevalence of that specific clinical feature. ID = intellectual disability. B) Four individuals diagnosed with Koolen-de Vries syndrome are presented here (written informed consent for the publication of these facial images was obtained). These were the facial image, using the phenotypic data, and finally, the PhenoScore, which combines both. Furthermore, heatmaps are generated using local interpretable model-agnostic explanations (LIME) to see which facial areas are most important according to our model, where blue correlates with KdVS and red areas correlate a summarized heatmap was generated to investigate the overall most important facial and phenotypic features. We averaged the heatmaps of the five individuals with Koolen-de Vries with the highest prediction. Next to that, to obtain the most important clinical features, too, we averaged the LIME regression coefficient for the different symptoms of the five highest-scoring individuals based on HPO. Shown clinical features are ordered based on importance, and the size of the randomly selected from the included dataset without any selection criterion. C) For the four randomly selected individuals, three predictions are shown: using with controls. The nose and eyes are clearly prioritized, corresponding to the known dysmorphic features in Koolen-de Vries. Furthermore, the most important clinical features are shown for each individual and the contribution (corresponding to the LIME regression coefficient) of that feature to the prediction. D) Finally, circle indicates the relative importance of the feature.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.24.22281480; this version posted October 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license. i length < 3rd percentile HPO: 0.79 HPO: 0.79 aesarian Correlated with syndrome HPO: 0.87 reech pi besity Ptosis mall for AUC Both: 0.78 AUC Both: 0.90 Feeding difficulties in infancy Intellectual disability, mild Face: 0.54 Face: 0.62 ace: 0.6 Caesarian section afe-au-lait spot rpoplasia of the HPO: 0.64 крмзв ттанжи HPO: 0.99 NOS oint laxity AUC Both: 0.68 AUC Both: 0.99 Generalized remature birt Joint laxity HPO: 0.9 HPO: 0.86 HPO: 0.71 distress with control eeding dif EEG abn Correlated Hypern Nevus ace: 0.59 ace: 0.82 AUC Both: 0.92 AUC Both: 0.70 dIHd хєхаа iastrostomy tube feeding n infancy Face: 0.7 Face: 0.9 ophageal reflux atent ductus arte esarian sectio HPO: 0.88 **ANDA** HPO: 0.82 TISNAX HPO: 0.74 Motor delay stature strabismus AUC Both: 0.89 AUC Both: 0.84 AUC Both: 0.78 ineralized tonic seizure ieneralized clonic seizur ncreased body weight sralized hypo ailure to thr Strabismus Birth length 97th percen HPO: 0.98 EG abnormalit HPO: 0.69 otropia HPO: 0.86 Face: 0.55 Obesity Face: 0.52 ace: 0.91 AUC Both: 0.68 AUC Both: 0.86 ts⊃aq 8ан) τл noderate Face: 0.89 Face: 0.48 Generalized hypo Motor delay Hypotonia Brachycephaly HPO: 0.87 belayed spee НРО: 0.76 layed fine HPO: 0.86 ral motor h eeding dit es valgus **Hypotonia** εταα **EBXOI**I (əsuəssim) IBTAS AUC Both: 0.89 AUC Both: 0.82 AUC Both: 0.87 Imbilical hernia Inguinal hernia Specific learn elayed speech anguage devel HPO: 0.49 HPO: 0.92 Face: 0.64 HPO: 0.9 Face: 0.71 Face: 0.88 AUC Both: 0.95 AUC Both: 0.91 иертзг снрз CAW Face: 0.42 Face: 0.70 Generalized hypotonia Face: 0.65 Decreased body weigh ctual disability HPO: 0.73 arse scalp hair Feeding difficu Motor delay HPO: 0.88 HPO: 0.94 ттмнэ **Α61ΤΟΑ** ∀ЯЛЧ AUC Both: 0.89 AUC Both: 0.96 AUC Both: 0.88 ebrile seizure (within the age ange of 3 months to 6 years) ricular septal defec Intrauterine growth Feeding difficulties lized hvi ocalcemia HPO: 0.88 sal speech HPO: 0.80 Face: 0.97 HPO: 0.85 Short statu Small hand

AUC Both: 0.81

AUC Both: 0.87

AUC Both: 0.99

AUC Both: 0.52

AUC Both: 0.91

Face: 0.79

22d11 deletion

ace: 0.86

атаіяч

AUC Both: 0.81

Face: 0.51

рүвкіа

are the average LIME heatmaps of the five individuals per genetic syndrome with the highest predictive score based on the facial data alone. For the phenotypic data, the positive LIME regression coefficients per symptom were averaged of the top-scoring five individuals based on the phenotypic data. The standard face Figure 3: The heatmaps and most important clinical features of all 26 genetic syndromes included in this study are displayed in this figure. The facial heatmaps used as background is a non-existent person generated using StyleGAN. [74].

ace: 0.87

τειο

MECP2 duplication

AUC Both: 0.88

Face: 0.46

DTWdd



Figure 4: The performance of the SVM using both facial- and HPO features with different sizes of the training set is shown here. Both the median Brier score and the median AUC improve if the number of individuals to train on is larger — as would be expected. Interestingly, only three individuals are needed for an already acceptable classification performance.



Figure 5: Above: a lollipop plot (generated using St. Jude's ProteinPaint) of the genetic variants currently collected using the ADNP HDG website [62]. Of the 58 included individuals, 29 had a variant in the c.2000-2340 region, indicated by others as having a different methylation signature than variants outside this region [56]. Using only the HPO module of our PhenoScore framework, we first matched the groups on gender-, ethnicity- and age when possible to create two groups of the same size (29 vs. 29). We then trained a classifier on the two groups and found a significant difference (Brier score of 0.24, AUC of 0.71, p = 0.01). Below: the most important clinical features according to our model (determined using LIME) and the corresponding prevalence in both groups.

$\mathbf{5}$ Supplementary data 433

5.1Supplementary methods 434

5.1.1Permutation test for hypothesis testing 435

To provide a *p*-value for our classification results and to enable the use of our framework for 436 the recognition of specific (sub)groups in genetic syndromes, we developed a permutation test -437 inspired by the test described by Lopez-Paz & Oquab [75]. For every group of individuals of interest, 438 a group of age-, sex- and ethnicity-matched controls is sampled from our control database. We 439 extract the facial features using VGGFace2 and calculate the HPO similarity using the Resnik score, 440 after which a SVM is trained using cross-validation. A grid search for the optimal hyperparameters 441 is performed, and the Brier score is calculated for this combination of the group of individuals of 442 interest and the matched controls. This process is precisely the same as in our standard analysis. 443 Next, we randomly permute the labels (here, the labels correspond to whether an individual has the 444 syndrome or is a control) 100 times. We ensure that the number of positive and negative classes is 445 the same as in our original distribution of the labels. For each permutation, we repeat the process 446 of training a SVM to obtain a Brier score. We then perform a one-sided Mann-Whitney U test to 447 quantify the probability of the classification results being statistically significantly smaller (since 448 it is the Brier score we are comparing) than the randomly permuted scores. 449

To further strengthen our permutation test, we repeat the process five times in total, randomly 450 sampling matched controls from our database in each repetition. The five obtained p values were 451 then combined using Fisher's method [76] to gather a definitive *p*-value for this classification task 452 and, therefore, for this specific group of individuals of interest. 453

For the analyses for both SATB1 and ADNP, we do not need to sample controls from our 454 database. However, these datasets are usually imbalanced, sometimes leading to problems for the 455 classifier. We therefore undersample the majority class to the size of the minority class by matching 456 the individuals on ethnicity, sex and age (in that order) and increase the number of permutations 457 of the labels to 1000 (since we cannot repeatedly sample controls). 458

Finally, to have a negative control group for this test, we randomly sampled individuals from 459 our control database and calculated p-values for those. We did this for different cohort sizes (n =460 3, 5, 10, 20 and 40) for in total 50 trials. Of those 50 trials, two resulted in a p-value smaller than 461 0.05 - exactly what would be expected by random chance in this number of trials. This shows that 462 our approach leads to the to-be-expected number of false alarms. 463

Genetic syndrome	PMID of used publications
22q11 deletion	$15831592, 17041934, 18636631, 1956057, 21200182, 25317860, 3816857, 12548732 \ [77-84]$
ACTL6A	28649782 [85]
ADAT3	23620220,26842963 [86, 87]
ADNP	$24531329,25217958,27031564,29724491\ [55,\ 88-90]$
ANKRD11	$19920853, 21527850, 21654729, 22307766, 23494856, 26269249 \ [91-96]$
ARID1B	$19034313, 22405089, 22426309, 22585544, 23906836, 24569609, 26395437, 26754677, 27112773, 28323383, 30055038, 30349098, 31981384, 32339967 \ \left[97-110\right]$
CHD3	$30397230, 32483341 \ [111, 112]$
CHD8	23160955,24998929,31001818,31721432,Not published [113–116]
DDX3X	26235985 [117]
DYRK1A	18405873,21294719,23099646,23160955,25707398,Not published [113, 118–121]
EHMT1	22670141, Not published [122]
FBX011	$27479843,28343630\ [123,\ 124]$
KANSL1	$16906164, 17601928, 18628315, 21094706, 22544363, 26306646, Not published \ [51, 53, 125-128]$
KDM3B	30929739 [129]
MECP2 duplication	$18854860, 18985075\ [130,\ 131]$
MED13L	$23403903, 24781760, 25712080, 28645799, 29511999, 29959045\ [132-137]$
PACS1	26842493 [138]
PHIP	29209020 [139]
PPM1D	28343630 [124]
PURA	27148565,29097605,29150892[140-142]
SATB1 (missense + truncating)	33513338 [54]
SON	$24896178, 27256762, 27545680 \ \left[4, \ 143-145\right]$
TRIO	$26721934, 27418539 \ [146, 147]$
WAC	23033978, 26264232, 26757981 [2, 148, 149]
YY1	$21076407, 28575647 \ [1, \ 150]$

as the control dataset, instead of the controls from the Radboud university medical center. The results are slightly worse than on the RUMC control dataset, as expected, since not for not every individual, a control is available because the RUMC control dataset is significantly larger than the number of individuals Supplementary table 2: The Brier scores of the support vector machine (SVM) classifier are displayed here, now with the other individuals included in this study included in this study.

22Q11 ACTL6A			
ACTL6A	0.224	0.120	0.120
	0.248	0.231	0.219
ADAT3	0.165	0.073	0.067
ADNP	0.226	0.187	0.178
ANKRD11	0.253	0.148	0.146
ARID1B	0.175	0.100	0.091
CHD3	0.222	0.154	0.154
CHD8	0.239	0.160	0.126
DDX3X	0.226	0.022	0.024
DYRK1A	0.256	0.182	0.159
EHMT1	0.191	0.124	0.107
FBX011	0.273	0.218	0.224
KANSL1	0.122	0.122	0.105
KDM3B	0.283	0.167	0.161
MECP2	0.167	0.252	0.199
MED13L	0.250	0.186	0.177
PACS1	0.277	0.197	0.198
PHIP	0.198	0.141	0.139
PPM1D	0.255	0.125	0.116
PURA	0.202	0.118	0.126
SATB1 (missense)	0.263	0.119	0.113
SATB1 (truncating)	0.137	0.205	0.186
NOS	0.237	0.135	0.121
TRIO	0.132	0.178	0.173
WAC	0.137	0.193	0.171
YY1	0.260	0.294	0.274

analysis. This is the only variant in which PhenoScore disagrees with the outcome of a functional test, with a low score (0.06) – probably due to the phenotype The two ARID1B variants were both regarded as benign: one after methylation analysis (negative), the other variant since the individual was diagnosed with Supplementary table 3: The 15 individuals with a VUS in one of the 26 included syndromes are displayed here, including the genetic information and the PhenoScore. For most, pathogenicity is still not clear at the time of writing, but for four, additional (genetic) testing has led to a change in pathogenicity class. fragile X syndrome at a later stage. PhenoScore agrees with both assessments with a low prediction (0.03 and 0.02). Next to that, a splice variant in CHD8 with a high PhenoScore of 0.89 was deemed pathogenic after RNA analysis was performed. Finally, a variant in EHMT1 was deemed pathogenic after methylation not particularly matching.

Curr		ται τατά (πετα-/ βτοιείπ) Οταροπητατιστι από το Οπη	variant ((non)coung) variant (nuvA/protein) Classification Curr
iant unclear, c	class 3 Variant unclear, c	p.(Gly1093Arg) class 3 Variant unclear, c	NM.001256182.1:c.3277G>A p.(Gly1093Arg) class 3 Variant unclear, c
iant unclear	class 3 Variant unclear	p.(Cys1046Leu) class 3 Variant unclear	NM_013275.5:c.3137_3138delinsTG p.(Cys1046Leu) class 3 Variant unclear
iant unclea	class 3 Variant unclea	p.(Thr1721Met) class 3 Variant unclea	NM-013275.5:c.5162C>T p.(Thr1721Met) class 3 Variant unclea
iant unclear	class 3 Variant unclear	p.(Pro756Ala) class 3 Variant unclear	NM_020732.3:c.2266C>G p.(Pro756Ala) class 3 Variant unclean
er genetic	class 3 Other genetic	p.(Ser994Leu) class 3 Other genetic	$\label{eq:NM_001346813.1:c.2981C>T} p.(Ser994Leu) \qquad class 3 \qquad Other genetic - p.(Ser994Leu) = 0.0000000000000000000000000000000000$
hogenic aft	class 3 Pathogenic aft	p.? class 3 Pathogenic aft	NM_001170629.1:c.4062+5G>C p.? class 3 Pathogenic aft
iant uncle	class 3 Variant uncle	p.(Arg326Cys) class 3 Variant uncle	$\label{eq:NM_001356.4} \mathrm{NM_001356.4} (\mathrm{DDX3X}) : \mathrm{c.976C > T} \qquad \mathrm{p.(Arg326Cys)} \qquad \mathrm{class} \ 3 \qquad \mathrm{Variant} \ \mathrm{unclein} = \mathrm{variant} \ uncl$
iant uncl	class 3 Variant uncl	p.(Ile522Thr) class 3 Variant uncl	NM.001356.4:c.1565T>C p.(Ile522Thr) class 3 Variant uncl
hogenic a	class 3 Pathogenic a	p.(Leu758Pro) class 3 Pathogenic a	NM_024757.4:c.2273T>C p.(Leu758Pro) class 3 Pathogenic a
iant uncl	class 3 Variant uncl	p.(Arg796Trp) class 3 Variant uncl	$\label{eq:nonlinear} NM_016604.3; c.2386A>T \\ p.(Arg796Trp) \\ class 3 \\ Variant uncl$
iant uncl	class 3 Variant uncl	p.(Val732=) class 3 Variant uncl	$\label{eq:NM-017934.6:c.2196A>G} {\rm p.(Val732=)} \qquad {\rm class \ 3} \qquad {\rm Variant \ uncl}$
iant uncl	class 3 Variant uncl	p.(Arg250*) class 3 Variant uncl	$\label{eq:nonlinear} \mathrm{NM}_{-003620.3:c.748C>T} \qquad \mathrm{p.(Arg250*)} \qquad \mathrm{class} \; 3 \qquad \mathrm{Variant} \; \mathrm{uncl}$
iant unc	class 3 Variant unc	p.(Glu109Asp) class 3 Variant unc	NM_005859.4:c.327G>T p.(Glu109Asp) class 3 Variant unc
iant uncl	class 3 Variant unch	p.(Arg1078Gln) class 3 Variant uncl	NM_007118.3:c.3233G>A p.(Arg1078Gln) class 3 Variant uncl
iant unc	class 3 Variant unc	p.(Met598Val) class 3 Variant unc	NM_016628.4(WAC):c.1792A>G p.(Met598Val) class 3 Variant unc

medRxiv preprint doi: https://doi.org/10.1101/2022.10.24.22281480; this version posted October 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

464 References

- [1] Vissers LELM, de Ligt J, Gilissen C, Janssen I, Steehouwer M, de Vries P, et al. A de novo
 paradigm for mental retardation. Nat Genet. 2010 Dec;42(12):1109-12.
- de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012
 Nov;367(20):1921-9.
- [3] Rauch A, Wieczorek D, Graf E, Wieland T, Endele S, Schwarzmayr T, et al. Range of genetic
 mutations associated with severe non-syndromic sporadic intellectual disability: an exome
 sequencing study. Lancet. 2012 Nov;380(9854):1674-82.
- [4] Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BWM, Willemsen MH,
 et al. Genome sequencing identifies major causes of severe intellectual disability. Nature.
 2014 Jul;511(7509):344-7.
- [5] Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for
 the interpretation of sequence variants: a joint consensus recommendation of the American
 College of Medical Genetics and Genomics and the Association for Molecular Pathology.
 Genet Med. 2015 May;17(5):405-24.
- [6] Beaumont RN, Wright CF. Estimating diagnostic noise in panel-based genomic analysis.
 Genet Med. 2022 Aug.
- [7] McGuire AL, Gabriel S, Tishkoff SA, Wonkam A, Chakravarti A, Furlong EEM, et al. The
 road ahead in genetics and genomics. Nat Rev Genet. 2020 Oct;21(10):581-96.
- [8] Logsdon GA, Vollger MR, Eichler EE. Long-read human genome sequencing and its appli cations. Nat Rev Genet. 2020 Oct;21(10):597-614.
- [9] 100,000 Genomes Project Pilot Investigators, Smedley D, Smith KR, Martin A, Thomas EA,
 McDonagh EM, et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care Preliminary Report. N Engl J Med. 2021 Nov;385(20):1868-80.
- [10] Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease causing potential of sequence alterations. Nat Methods. 2010 Aug;7(8):575-6.
- [11] Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method
 and server for predicting damaging missense mutations. Nat Methods. 2010 Apr;7(4):248-9.
- [12] Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on
 protein function using the SIFT algorithm. Nat Protoc. 2009 Jun;4(7):1073-81.

- [13] Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general frame work for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014
 Mar;46(3):310-5.
- [14] Robinson PN, Köhler S, Bauer S, Seelow D, Horn D, Mundlos S. The Human Phenotype
 Ontology: a tool for annotating and analyzing human hereditary disease. Am J Hum Genet.
 2008 Nov;83(5):610-5.
- [15] Leite AJdC, Pinto IP, Leijsten N, Ruiterkamp-Versteeg M, Pfundt R, de Leeuw N, et al.
 Diagnostic yield of patients with undiagnosed intellectual disability, global developmental
 delay and multiples congenital anomalies using karyotype, microarray analysis, whole exome
 sequencing from Central Brazil. PLoS One. 2022 Apr;17(4):e0266493.
- [16] Clift K, Macklin S, Halverson C, McCormick JB, Dabrh AMA, Hines S. Patients' views on
 variants of uncertain significance across indications. J Community Genet. 2020;11(2):139-45.
- [17] Makhnoon S, Garrett LT, Burke W, Bowen DJ, Shirts BH. Experiences of patients seeking to
 participate in variant of uncertain significance reclassification research. J Community Genet.
 2019 Apr;10(2):189-96.
- [18] van Dijk S, Timmermans DRM, Meijers-Heijboer H, Tibben A, van Asperen CJ, Otten W.
 Clinical Characteristics Affect the Impact of an Uninformative DNA Test Result: The Course
 of Worry and Distress Experienced by Women Who Apply for Genetic Testing for Breast
 Cancer. J Clin Oncol. 2006;24(22):3672-7.
- [19] Murray ML, Cerrato F, Bennett RL, Jarvik GP. Follow-up of carriers of BRCA1 and BRCA2
 variants of unknown significance: variant reclassification and surgical decisions. Genet Med.
 2011 Dec;13(12):998-1005.
- [20] Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010
 Jul;363(4):301-4.
- ⁵¹⁹ [21] Ashley EA. Towards precision medicine. Nat Rev Genet. 2016 Aug;17(9):507-22.
- [22] Brittain HK, Scott R, Thomas E. The rise of the genome and personalised medicine. Clin
 Med. 2017 Dec;17(6):545-51.
- [23] Coudray N, Ocampo PS, Sakellaropoulos T, Narula N, Snuderl M, Fenyö D, et al. Classifi cation and mutation prediction from non-small cell lung cancer histopathology images using
 deep learning. Nat Med. 2018 Oct;24(10):1559-67.
- [24] Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in
 radiology. Nat Rev Cancer. 2018 Aug;18(8):500-10.

- [25] Killock D. AI outperforms radiologists in mammographic screening. Nat Rev Clin Oncol.
 2020 Mar;17(3):134.
- [26] Lu MY, Chen TY, Williamson DFK, Zhao M, Shady M, Lipkova J, et al. AI-based pathology
 predicts origins for cancers of unknown primary. Nature. 2021 Jun;594(7861):106-10.
- [27] Poplin R, Chang PC, Alexander D, Schwartz S, Colthurst T, Ku A, et al. A universal SNP and
 small-indel variant caller using deep neural networks. Nat Biotechnol. 2018 Nov;36(10):983-7.
- [28] Sundaram L, Gao H, Padigepati SR, McRae JF, Li Y, Kosmicki JA, et al. Predicting the clin ical impact of human mutation with deep neural networks. Nat Genet. 2018 Aug;50(8):1161 70.
- [29] Wick RR, Judd LM, Holt KE. Performance of neural network basecalling tools for Oxford
 Nanopore sequencing. Genome Biol. 2019 Jun;20(1):129.
- [30] Köhler S, Schulz MH, Krawitz P, Bauer S, Dölken S, Ott CE, et al. Clinical diagnostics
 in human genetics with semantic similarity searches in ontologies. Am J Hum Genet. 2009
 Oct;85(4):457-64.
- [31] Robinson PN, Köhler S, Oellrich A, Sanger Mouse Genetics Project, Wang K, Mungall
 CJ, et al. Improved exome prioritization of disease genes through cross-species phenotype
 comparison. Genome Res. 2014 Feb;24(2):340-8.
- [32] Zemojtel T, Köhler S, Mackenroth L, Jäger M, Hecht J, Krawitz P, et al. Effective diagnosis
 of genetic disease by computational phenotype analysis of the disease-associated genome. Sci
 Transl Med. 2014 Sep;6(252):252ra123.
- [33] Smedley D, Robinson PN. Phenotype-driven strategies for exome prioritization of human
 Mendelian disease genes. Genome Med. 2015 Jul;7(1):81.
- [34] Smedley D, Jacobsen JOB, Jäger M, Köhler S, Holtgrewe M, Schubach M, et al. Next generation diagnostics and disease-gene discovery with the Exomiser. Nat Protoc. 2015
 Dec;10(12):2004-15.
- [35] Hsieh TC, Mensah MA, Pantel JT, Aguilar D, Bar O, Bayat A, et al. PEDIA: prioritization
 of exome data by image analysis. Genet Med. 2019 Dec;21(12):2807-14.
- [36] Robinson PN, Ravanmehr V, Jacobsen JOB, Danis D, Zhang XA, Carmody LC, et al. In terpretable Clinical Genomics with a Likelihood Ratio Paradigm. Am J Hum Genet. 2020
 Sep;107(3):403-17.

[37] Ferry Q, Steinberg J, Webber C, FitzPatrick DR, Ponting CP, Zisserman A, et al. Diagnos tically relevant facial gestalt information from ordinary photos. Elife. 2014 Jun;3:e02020.

- [38] Dudding-Byth T, Baxter A, Holliday EG, Hackett A, O'Donnell S, White SM, et al. Com puter face-matching technology using two-dimensional photographs accurately matches the
 facial gestalt of unrelated individuals with the same syndromic form of intellectual disability.
 BMC Biotechnol. 2017 Dec;17(1):90.
- [39] van der Donk R, Jansen S, Schuurs-Hoeijmakers JHM, Koolen DA, Goltstein LCMJ, Hoischen
 A, et al. Next-generation phenotyping using computer vision algorithms in rare genomic
 neurodevelopmental disorders. Genet Med. 2018 Dec.
- [40] Gurovich Y, Hanani Y, Bar O, Nadav G, Fleischer N, Gelbman D, et al. Identifying facial
 phenotypes of genetic disorders using deep learning. Nat Med. 2019 Jan;25(1):60-4.
- [41] Dingemans AJM, Stremmelaar DE, van der Donk R, Vissers LELM, Koolen DA, Rump P,
 et al. Quantitative facial phenotyping for Koolen-de Vries and 22q11.2 deletion syndrome.
 Eur J Hum Genet. 2021 Feb;29(9):1418-23.
- [42] Hsieh TC, Bar-Haim A, Moosa S, Ehmke N, Gripp KW, Pantel JT, et al. GestaltMatcher
 facilitates rare disease matching using facial phenotype descriptors. Nat Genet. 2022 Feb.
- ⁵⁷³ [43] Claes P, Roosenboom J, White JD, Swigut T, Sero D, Li J, et al. Genome-wide mapping of ⁵⁷⁴ global-to-local genetic effects on human facial shape. Nat Genet. 2018 Mar;50(3):414-23.
- ⁵⁷⁵ [44] White JD, Indencleef K, Naqvi S, Eller RJ, Hoskens H, Roosenboom J, et al. Insights into ⁵⁷⁶ the genetic architecture of the human face. Nat Genet. 2021 Jan;53(1):45-53.
- [45] Naqvi S, Sleyp Y, Hoskens H, Indencleef K, Spence JP, Bruffaerts R, et al. Shared heritability
 of human face and brain shape. Nat Genet. 2021 Jun;53(6):830-9.
- [46] Zhang M, Wu S, Du S, Qian W, Chen J, Qiao L, et al. Genetic variants underlying dif ferences in facial morphology in East Asian and European populations. Nat Genet. 2022
 Apr;54(4):403-11.
- [47] Vulto-van Silfhout AT, Hehir-Kwa JY, van Bon BWM, Schuurs-Hoeijmakers JHM, Meader S,
 Hellebrekers CJM, et al. Clinical significance of de novo and inherited copy-number variation.
 Hum Mutat. 2013 Dec;34(12):1679-87.
- [48] Ribeiro MT, Singh S, Guestrin C. "Why should i trust you?" Explaining the predictions
 of any classifier. In: Proceedings of the 22nd ACM SIGKDD international conference on
 knowledge discovery and data mining; 2016. p. 1135-44.

- [49] Ras G, Xie N, van Gerven M, Doran D. Explainable Deep Learning: A Field Guide for the
 Uninitiated. J Artif Intell Res. 2022 Jan;73:329-96.
- [50] Brier GW. Verification of forecasts expressed in terms of probability. Mon Weather Rev.
 1950.
- [51] Koolen DA, Kramer JM, Neveling K, Nillesen WM, Moore-Barton HL, Elmslie FV, et al. Mu tations in the chromatin modifier gene KANSL1 cause the 17q21.31 microdeletion syndrome.
 Nat Genet. 2012 Apr;44(6):639-41.
- [52] Zollino M, Orteschi D, Murdolo M, Lattante S, Battaglia D, Stefanini C, et al. Muta tions in KANSL1 cause the 17q21.31 microdeletion syndrome phenotype. Nat Genet. 2012
 Apr;44(6):636-8.
- [53] Koolen DA, DDD Study, Pfundt R, Linda K, Beunders G, Veenstra-Knol HE, et al. The
 Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdele tion versus a KANSL1 sequence variant. Eur J Hum Genet. 2016;24(5):652-9.
- [54] den Hoed J, de Boer E, Voisin N, Dingemans AJM, Guex N, Wiel L, et al. Mutation-specific
 pathophysiological mechanisms define different neurodevelopmental disorders associated with
 SATB1 dysfunction. Am J Hum Genet. 2021 Feb;108(2):346-56.
- [55] Helsmoortel C, Vulto-van Silfhout AT, Coe BP, Vandeweyer G, Rooms L, van den Ende J,
 et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat
 Genet. 2014 Apr;46(4):380-4.
- [56] Bend EG, Aref-Eshghi E, Everman DB, Rogers RC, Cathey SS, Prijoles EJ, et al. Gene
 domain-specific DNA methylation episignatures highlight distinct molecular entities of
 ADNP syndrome. Clin Epigenetics. 2019 Apr;11(1):64.
- [57] Breen MS, Garg P, Tang L, Mendonca D, Levy T, Barbosa M, et al. Episignatures Stratifying
 Helsmoortel-Van Der Aa Syndrome Show Modest Correlation with Phenotype. Am J Hum
 Genet. 2020 Sep;107(3):555-63.
- [58] Jagadeesh KA, Birgmeier J, Guturu H, Deisseroth CA, Wenger AM, Bernstein JA, et al.
 Phrank measures phenotype sets similarity to greatly improve Mendelian diagnostic disease
 prioritization. Genet Med. 2019 Feb;21(2):464-70.
- [59] Lyra PCM Jr, Nepomuceno TC, de Souza MLM, Machado GF, Veloso MF, Henriques TB,
 et al. Integration of functional assay data results provides strong evidence for classification
 of hundreds of BRCA1 variants of uncertain significance. Genet Med. 2021 Feb;23(2):306-15.

- [60] Frederiksen JH, Jensen SB, Tümer Z, Hansen TVO. Classification of MSH6 Variants of
 Uncertain Significance Using Functional Assays. Int J Mol Sci. 2021 Aug;22(16).
- [61] Caswell RC, Gunning AC, Owens MM, Ellard S, Wright CF. Assessing the clinical utility
 of protein structural analysis in genomic variant classification: experiences from a diagnostic
 laboratory. Genome Med. 2022 Jul;14(1):77.
- [62] Dingemans AJM, Stremmelaar DE, Vissers LELM, Jansen S, Nabais Sá MJ, van Remortele
 A, et al. Human disease genes website series: An international, open and dynamic library
 for up-to-date clinical information. Am J Med Genet A. 2021 Jan.
- [63] McKusick VA. Mendelian Inheritance in Man and its online version, OMIM. Am J Hum
 Genet. 2007 Apr;80(4):588-604.
- [64] Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, et al. DECIPHER:
 Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources.
 Am J Hum Genet. 2009 Apr;84(4):524-33.
- [65] Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al. GeneRe views[®]. Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al.,
 editors. Seattle (WA): University of Washington, Seattle; 2010.
- [66] Côté RA, Robboy S. Progress in medical information management. Systematized nomencla ture of medicine (SNOMED). JAMA. 1980;243(8):756-62.
- [67] Parkhi OM, Vedaldi A, Zisserman A. Deep Face Recognition. Proceedings of the British
 Machine Vision Conference 2015. 2015:41.1-41.12.
- [68] Cao, Shen, Xie, Parkhi, Zisserman. VGGFace2: A Dataset for Recognising Faces across
 Pose and Age. In: 2018 13th IEEE International Conference on Automatic Face & Gesture
 Recognition (FG 2018). vol. 0; 2018. p. 67-74.
- [69] Dingemans AJM, de Vries BBA, Vissers LEL, van Gerven MAJ, Hinne M. Comparing
 facial feature extraction methods in the diagnosis of rare genetic syndromes. medRxiv. 2022
 Aug:2022.08.26.22279217.
- [70] Resnik P. Semantic Similarity in a Taxonomy: An Information-Based Measure and its
 Application to Problems of Ambiguity in Natural Language. J Artif Intell Res. 1999 Jul;11:95 130.
- [71] Pesquita C, Faria D, Bastos H, Ferreira AEN, Falcão AO, Couto FM. Metrics for GO based
 protein semantic similarity: a systematic evaluation. BMC Bioinformatics. 2008 Apr;9 Suppl
 5:S4.

- [72] Arvai, Kevin and Borroto, Carlos and Gainullin, Vladimir and Retterer, Kyle. Phenopy;
 2019.
- [73] Manders P, Lutomski JE, Smit C, Swinkels DW, Zielhuis GA. The Radboud biobank: A
 central facility for disease-based biobanks to optimise use and distribution of biomaterial for
 scientific research in the Radboud university medical center, Nijmegen. Open J Bioresour.
 2018 Feb;5.
- [74] Karras T, Laine S, Aila T. A Style-Based Generator Architecture for Generative Adversarial
 Networks. IEEE Trans Pattern Anal Mach Intell. 2021 Dec;43(12):4217-28.
- [75] Lopez-Paz D, Oquab M. Revisiting Classifier Two-Sample Tests. arXiv. 2016 Oct.
- [76] Fisher RA. Statistical methods for research workers 12th edition. Oliver & Body; 1954.

[77] Rauch A, Zink S, Zweier C, Thiel CT, Koch A, Rauch R, et al. Systematic assessment of
 atypical deletions reveals genotype-phenotype correlation in 22q11.2. J Med Genet. 2005
 Nov;42(11):871-6.

- [78] Brunet A, Gabau E, Perich RM, Valdesoiro L, Brun C, Caballín MR, et al. Microdele tion and microduplication 22q11.2 screening in 295 patients with clinical features of DiGe orge/Velocardiofacial syndrome. Am J Med Genet A. 2006 Nov;140(22):2426-32.
- [79] Shprintzen RJ. Velo-cardio-facial syndrome: 30 Years of study. Dev Disabil Res Rev.
 2008;14(1):3-10.
- [80] Lipson AH, Yuille D, Angel M, Thompson PG, Vandervoord JG, Beckenham EJ. Velocardio facial (Shprintzen) syndrome: an important syndrome for the dysmorphologist to recognise.
 J Med Genet. 1991 Sep;28(9):596-604.
- [81] McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge
 syndrome/velocardiofacial syndrome). Medicine. 2011 Jan;90(1):1-18.
- [82] Grassi MS, Jacob CM, Kulikowski LD, Pastorino AC, Dutra RL, Miura N, et al. Congenital
 Heart Disease as a Warning Sign for the Diagnosis of the 22q11.2 Deletion. Arq Bras Cardiol.
 2014 Nov;103(5):382-90.
- [83] Meinecke P, Beemer FA, Schinzel A, Kushnick T. The velo-cardio-facial (Shprintzen) syn drome. Clinical variability in eight patients. Eur J Pediatr. 1986 Dec;145(6):539-44.
- [84] Bartsch O, Nemecková M, Kocárek E, Wagner A, Puchmajerová A, Poppe M, et al. DiGeorge/velocardiofacial syndrome: FISH studies of chromosomes 22q11 and 10p14, and clinical
 reports on the proximal 22q11 deletion. Am J Med Genet A. 2003 Feb;117A(1):1-5.

- [85] Marom R, Jain M, Burrage LC, Song IW, Graham BH, Brown CW, et al. Heterozygous vari ants in ACTL6A, encoding a component of the BAF complex, are associated with intellectual
 disability. Hum Mutat. 2017 Oct;38(10):1365-71.
- [86] Alazami AM, Hijazi H, Al-Dosari MS, Shaheen R, Hashem A, Aldahmesh MA, et al. Muta tion in ADAT3, encoding adenosine deaminase acting on transfer RNA, causes intellectual
 disability and strabismus. J Med Genet. 2013 Jul;50(7):425-30.
- [87] El-Hattab AW, Saleh MA, Hashem A, Al-Owain M, Asmari AA, Rabei H, et al. ADAT3 related intellectual disability: Further delineation of the phenotype. Am J Med Genet A.
 2016 May;170A(5):1142-7.
- [88] Coe BP, Witherspoon K, Rosenfeld JA, van Bon BW, Vulto-van Silfhout AT, Bosco P,
 et al. Refining analyses of copy number variation identifies specific genes associated with
 developmental delay. Nat Genet. 2014 Oct;46(10):1063-71.
- [89] Krajewska-Walasek M, Jurkiewicz D, Piekutowska-Abramczuk D, Kucharczyk M,
 Chrzanowska KH, Jezela-Stanek A, et al. Additional data on the clinical phenotype of
 Helsmoortel-Van der Aa syndrome associated with a novel truncating mutation in ADNP
 gene. Am J Med Genet A. 2016 Jun;170(6):1647-50.
- [90] Van Dijck A, Vulto-van Silfhout AT, Cappuyns E, van der Werf IM, Mancini GM, Tzschach
 A, et al. Clinical Presentation of a Complex Neurodevelopmental Disorder Caused by Mu tations in ADNP. Biol Psychiatry. 2019 Feb;85(4):287-97.
- [91] Willemsen MH, Fernandez BA, Bacino CA, Gerkes E, de Brouwer AP, Pfundt R, et al.
 Identification of ANKRD11 and ZNF778 as candidate genes for autism and variable cog nitive impairment in the novel 16q24.3 microdeletion syndrome. Eur J Hum Genet. 2010
 Apr;18(4):429-35.
- [92] Youngs EL, Hellings JA, Butler MG. ANKRD11 gene deletion in a 17-year-old male. Clin
 Dysmorphol. 2011 Jul;20(3):170-1.
- [93] Isrie M, Hendriks Y, Gielissen N, Sistermans EA, Willemsen MH, Peeters H, et al. Haploin sufficiency of ANKRD11 causes mild cognitive impairment, short stature and minor dysmor phisms. Eur J Hum Genet. 2012 Feb;20(2):131-3.
- [94] Sacharow S, Li D, Fan YS, Tekin M. Familial 16q24.3 microdeletion involving ANKRD11
 causes a KBG-like syndrome. Am J Med Genet A. 2012 Mar;158A(3):547-52.

[95] Khalifa M, Stein J, Grau L, Nelson V, Meck J, Aradhya S, et al. Partial deletion of ANKRD11
results in the KBG phenotype distinct from the 16q24.3 microdeletion syndrome. Am J Med
Genet A. 2013 Apr;161A(4):835-40.

- ⁷¹⁵ [96] Ockeloen CW, Willemsen MH, de Munnik S, van Bon BW, de Leeuw N, Verrips A, et al.
 ⁷¹⁶ Further delineation of the KBG syndrome caused by ANKRD11 aberrations. Eur J Hum
 ⁷¹⁷ Genet. 2015 Sep;23(9):1270.
- [97] Nagamani SC, Erez A, Eng C, Ou Z, Chinault C, Workman L, et al. Interstitial deletion of
 6q25.2-q25.3: a novel microdeletion syndrome associated with microcephaly, developmental
 delay, dysmorphic features and hearing loss. Eur J Hum Genet. 2009 May;17(5):573-81.
- [98] Hoyer J, Ekici AB, Endele S, Popp B, Zweier C, Wiesener A, et al. Haploinsufficiency of
 ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause
 of intellectual disability. Am J Hum Genet. 2012 Mar;90(3):565-72.
- [99] Santen GWE, Aten E, Sun Y, Almomani R, Gilissen C, Nielsen M, et al. Mutations in
 SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. Nat
 Genet. 2012 Mar;44(4):379-80.
- [100] Michelson M, Ben-Sasson A, Vinkler C, Leshinsky-Silver E, Netzer I, Frumkin A, et al. De lineation of the interstitial 6q25 microdeletion syndrome: refinement of the critical causative
 region. Am J Med Genet A. 2012 Jun;158A(6):1395-9.
- [101] Wieczorek D, Bögershausen N, Beleggia F, Steiner-Haldenstätt S, Pohl E, Li Y, et al. A
 comprehensive molecular study on Coffin-Siris and Nicolaides-Baraitser syndromes identifies
 a broad molecular and clinical spectrum converging on altered chromatin remodeling. Hum
 Mol Genet. 2013 Dec;22(25):5121-35.
- [102] Vals MA, Oiglane-Shlik E, Nõukas M, Shor R, Peet A, Kals M, et al. Coffin-Siris Syndrome
 with obesity, macrocephaly, hepatomegaly and hyperinsulinism caused by a mutation in the
 ARID1B gene. Eur J Hum Genet. 2014 Nov;22(11):1327-9.
- [103] Ben-Salem S, Sobreira N, Akawi NA, Al-Shamsi AM, John A, Pramathan T, et al. Gonadal
 mosaicism in ARID1B gene causes intellectual disability and dysmorphic features in three
 siblings. Am J Med Genet A. 2016 Jan;170A(1):156-61.
- [104] Ronzoni L, Tagliaferri F, Tucci A, Baccarin M, Esposito S, Milani D. Interstitial 6q25 microdeletion syndrome: ARID1B is the key gene. Am J Med Genet A. 2016 May;170A(5):125761.

- [105] Gripp KW, Baker L, Telegrafi A, Monaghan KG. The role of objective facial analysis using
 FDNA in making diagnoses following whole exome analysis. Report of two patients with
 mutations in the BAF complex genes. Am J Med Genet A. 2016 Jul;170(7):1754-62.
- [106] Zweier M, Peippo MM, Pöyhönen M, Kääriäinen H, Begemann A, Joset P, et al. The
 HHID syndrome of hypertrichosis, hyperkeratosis, abnormal corpus callosum, intellectual
 disability, and minor anomalies is caused by mutations in ARID1B. Am J Med Genet A.
 2017 May;173(5):1440-3.
- [107] Määttänen L, Hietala M, Ignatius J, Arvio M. A 69-year-old woman with Coffin-Siris syn drome. Am J Med Genet A. 2018 Aug;176(8):1764-7.
- [108] van der Sluijs PJ, Jansen S, Vergano SA, Adachi-Fukuda M, Alanay Y, AlKindy A, et al. The
 ARID1B spectrum in 143 patients: from nonsyndromic intellectual disability to Coffin-Siris
 syndrome. Genet Med. 2019 Jun;21(6):1295-307.
- ⁷⁵⁵ [109] Liu X, Hu G, Ye J, Ye B, Shen N, Tao Y, et al. De Novo ARID1B mutations cause growth ⁷⁵⁶ delay associated with aberrant Wnt/β -catenin signaling. Hum Mutat. 2020 May;41(5):1012-⁷⁵⁷ 24.
- [110] Lian S, Ting TW, Lai AHM, Tan ES, Wei H, Cham B, et al. Coffin-Siris Syndrome-1:
 Report of five cases from Asian populations with truncating mutations in the ARID1B gene.
 J Neurol Sci. 2020 Jul;414:116819.
- [111] Snijders Blok L, Rousseau J, Twist J, Ehresmann S, Takaku M, Venselaar H, et al. CHD3
 helicase domain mutations cause a neurodevelopmental syndrome with macrocephaly and
 impaired speech and language. Nat Commun. 2018 Nov;9(1):4619.
- [112] Drivas TG, Li D, Nair D, Alaimo JT, Alders M, Altmüller J, et al. A second cohort of
 CHD3 patients expands the molecular mechanisms known to cause Snijders Blok-Campeau
 syndrome. Eur J Hum Genet. 2020 Oct;28(10):1422-31.
- [113] O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex targeted
 sequencing identifies recurrently mutated genes in autism spectrum disorders. Science. 2012
 Dec;338(6114):1619-22.
- [114] Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, Penn O, et al. Disruptive CHD8
 mutations define a subtype of autism early in development. Cell. 2014 Jul;158(2):263-76.
- [115] Douzgou S, Liang HW, Metcalfe K, Somarathi S, Tischkowitz M, Mohamed W, et al. The
 clinical presentation caused by truncating CHD8 variants. Clin Genet. 2019 Jul;96(1):72-84.

[116] Ostrowski PJ, Zachariou A, Loveday C, Beleza-Meireles A, Bertoli M, Dean J, et al. The 774 CHD8 overgrowth syndrome: A detailed evaluation of an emerging overgrowth phenotype in 775 27 patients. Am J Med Genet C Semin Med Genet. 2019 Dec;181(4):557-64. 776 [117] Snijders Blok L, Madsen E, Juusola J, Gilissen C, Baralle D, Reijnders MR, et al. Mutations 777 in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific 778 Effects on Wnt Signaling. Am J Hum Genet. 2015 Aug;97(2):343-52. 779 [118] Møller RS, Kübart S, Hoeltzenbein M, Heye B, Vogel I, Hansen CP, et al. Truncation of the 780 Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. Am 781 J Hum Genet. 2008 May;82(5):1165-70. 782 [119] van Bon BW, Hoischen A, Hehir-Kwa J, de Brouwer AP, Ruivenkamp C, Gijsbers AC, et al. 783 Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly. Clin Genet. 2011 Mar;79(3):296-9. 785 [120] Courcet JB, Faivre L, Malzac P, Masurel-Paulet A, Lopez E, Callier P, et al. The DYRK1A 786 gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy. J 787 Med Genet. 2012 Dec;49(12):731-6. 788 [121] van Bon BW, Coe BP, Bernier R, Green C, Gerdts J, Witherspoon K, et al. Disruptive de 789 novo mutations of DYRK1A lead to a syndromic form of autism and ID. Mol Psychiatry. 790 2016 Jan;21(1):126-32. 791 [122] Willemsen MH, Vulto-van Silfhout AT, Nillesen WM, Wissink-Lindhout WM, van Bokhoven 792 H, Philip N, et al. Update on Kleefstra Syndrome. Mol Syndromol. 2012 Apr;2(3-5):202-12. 793 [123] Lelieveld SH, Reijnders MR, Pfundt R, Yntema HG, Kamsteeg EJ, de Vries P, et al. Meta-794 analysis of 2,104 trios provides support for 10 new genes for intellectual disability. Nat 795 Neurosci. 2016 Sep;19(9):1194-6. 796 [124] Jansen S, Geuer S, Pfundt R, Brough R, Ghongane P, Herkert JC, et al. De Novo Truncating 797 Mutations in the Last and Penultimate Exons of PPM1D Cause an Intellectual Disability 798 Syndrome. Am J Hum Genet. 2017 Apr;100(4):650-8. 799 [125] Koolen DA, Vissers LEL, Pfundt R, de Leeuw N, Knight SJL, Regan R, et al. A new chromo-800 some 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. 801 Nat Genet. 2006;38(9):999-1001. 802 [126] Hoyer J, Dreweke A, Becker C, Göhring I, Thiel CT, Peippo MM, et al. Molecular karyotyping 803 in patients with mental retardation using 100K single-nucleotide polymorphism arrays. J Med 804

Genet. 2007 Oct;44(10):629-36.

- [127] Koolen DA, Sharp AJ, Hurst JA, Firth HV, Knight SJL, Goldenberg A, et al. Clinical
 and molecular delineation of the 17q21.31 microdeletion syndrome. J Med Genet. 2008
 Nov;45(11):710-20.
- [128] Dubourg C, Sanlaville D, Doco-Fenzy M, Le Caignec C, Missirian C, Jaillard S, et al. Clinical
 and molecular characterization of 17q21.31 microdeletion syndrome in 14 French patients
 with mental retardation. Eur J Med Genet. 2011 Mar;54(2):144-51.
- [129] Diets IJ, van der Donk R, Baltrunaite K, Waanders E, Reijnders MRF, Dingemans AJM,
 et al. De Novo and Inherited Pathogenic Variants in KDM3B Cause Intellectual Disability,
 Short Stature, and Facial Dysmorphism. Am J Hum Genet. 2019 Apr;104(4):758-66.
- [130] Clayton-Smith J, Walters S, Hobson E, Burkitt-Wright E, Smith R, Toutain A, et al. Xq28
 duplication presenting with intestinal and bladder dysfunction and a distinctive facial appearance. Eur J Hum Genet. 2009 Apr;17(4):434-43.
- [131] Lugtenberg D, Kleefstra T, Oudakker AR, Nillesen WM, Yntema HG, Tzschach A, et al.
 Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained
 XLMR and in 2% of male patients with severe encephalopathy. Eur J Hum Genet. 2009
 Apr;17(4):444-53.
- [132] Asadollahi R, Oneda B, Sheth F, Azzarello-Burri S, Baldinger R, Joset P, et al. Dosage
 changes of MED13L further delineate its role in congenital heart defects and intellectual
 disability. Eur J Hum Genet. 2013 Oct;21(10):1100-4.
- [133] van Haelst MM, Monroe GR, Duran K, van Binsbergen E, Breur JM, Giltay JC, et al.
 Further confirmation of the MED13L haploinsufficiency syndrome. Eur J Hum Genet. 2015
 Jan;23(1):135-8.
- [134] Cafiero C, Marangi G, Orteschi D, Ali M, Asaro A, Ponzi E, et al. Novel de novo heterozy gous loss-of-function variants in MED13L and further delineation of the MED13L haploin sufficiency syndrome. Eur J Hum Genet. 2015 Nov;23(11):1499-504.
- [135] Asadollahi R, Zweier M, Gogoll L, Schiffmann R, Sticht H, Steindl K, et al. Genotype phenotype evaluation of MED13L defects in the light of a novel truncating and a recurrent
 missense mutation. Eur J Med Genet. 2017 Sep;60(9):451-64.
- [136] Smol T, Petit F, Piton A, Keren B, Sanlaville D, Afenjar A, et al. MED13L-related in tellectual disability: involvement of missense variants and delineation of the phenotype.
 Neurogenetics. 2018 May;19(2):93-103.

[137] Tørring PM, Larsen MJ, Brasch-Andersen C, Krogh LN, Kibæk M, Laulund L, et al. Is
 MED13L-related intellectual disability a recognizable syndrome? Eur J Med Genet. 2019
 Feb:62(2):129-36.

- [138] Schuurs-Hoeijmakers JH, Landsverk ML, Foulds N, Kukolich MK, Gavrilova RH, Greville Heygate S, et al. Clinical delineation of the PACS1-related syndrome–Report on 19 patients.
 Am J Med Genet A. 2016 Mar;170(3):670-5.
- [139] Jansen S, Hoischen A, Coe BP, Carvill GL, Van Esch H, Bosch DGM, et al. A genotype-first
 approach identifies an intellectual disability-overweight syndrome caused by PHIP haploinsufficiency. Eur J Hum Genet. 2018 Jan;26(1):54-63.
- [140] Tanaka AJ, Bai R, Cho MT, Anyane-Yeboa K, Ahimaz P, Wilson AL, et al. De novo
 mutations in PURA are associated with hypotonia and developmental delay. Cold Spring
 Harb Mol Case Stud. 2015 Oct;1(1):a000356.
- [141] Reijnders MRF, Janowski R, Alvi M, Self JE, van Essen TJ, Vreeburg M, et al. PURA
 syndrome: clinical delineation and genotype-phenotype study in 32 individuals with review
 of published literature. J Med Genet. 2018 Feb;55(2):104-13.
- ⁸⁵² [142] Lee BH, Reijnders MRF, Abubakare O, Tuttle E, Lape B, Minks KQ, et al. Expanding the
 ⁸⁵³ neurodevelopmental phenotype of PURA syndrome. Am J Med Genet A. 2018 Jan;176(1):56⁸⁵⁴ 67.
- [143] Takenouchi T, Miura K, Uehara T, Mizuno S, Kosaki K. Establishing SON in 21q22.11 as
 a cause a new syndromic form of intellectual disability: Possible contribution to BraddockCarey syndrome phenotype. Am J Med Genet A. 2016 Oct;170(10):2587-90.
- [144] Kim JH, Shinde DN, Reijnders MRF, Hauser NS, Belmonte RL, Wilson GR, et al. De
 Novo Mutations in SON Disrupt RNA Splicing of Genes Essential for Brain Development
 and Metabolism, Causing an Intellectual-Disability Syndrome. Am J Hum Genet. 2016
 Sep;99(3):711-9.
- [145] Dingemans AJM, Truijen KMG, Kim JH, Alaçam Z, Faivre L, Collins KM, et al. Establishing
 the phenotypic spectrum of ZTTK syndrome by analysis of 52 individuals with variants in
 SON. Eur J Hum Genet. 2021 Sep.
- [146] Ba W, Yan Y, Reijnders MR, Schuurs-Hoeijmakers JH, Feenstra I, Bongers EM, et al. TRIO
 loss of function is associated with mild intellectual disability and affects dendritic branching
 and synapse function. Hum Mol Genet. 2016 Mar;25(5):892-902.

- [147] Pengelly RJ, Greville-Heygate S, Schmidt S, Seaby EG, Jabalameli MR, Mehta SG, et al.
 Mutations specific to the Rac-GEF domain of TRIO cause intellectual disability and micro cephaly. J Med Genet. 2016 Nov;53(11):735-42.
- [148] DeSanto C, D'Aco K, Araujo GC, Shannon N, Vernon H, Rahrig A, et al. WAC lossof-function mutations cause a recognisable syndrome characterised by dysmorphic features,
 developmental delay and hypotonia and recapitulate 10p11.23 microdeletion syndrome. J
 Med Genet. 2015 Nov;52(11):754-61.
- [149] Lugtenberg D, Reijnders MR, Fenckova M, Bijlsma EK, Bernier R, van Bon BW, et al. De
 novo loss-of-function mutations in WAC cause a recognizable intellectual disability syndrome
 and learning deficits in Drosophila. Eur J Hum Genet. 2016 Aug;24(8):1145-53.
- ⁸⁷⁸ [150] Gabriele M, Vulto-van Silfhout AT, Germain PL, Vitriolo A, Kumar R, Douglas E, et al. YY1
- Haploinsufficiency Causes an Intellectual Disability Syndrome Featuring Transcriptional and

⁸⁸⁰ Chromatin Dysfunction. Am J Hum Genet. 2017 Jun;100(6):907-25.